STOCK TITAN

Wellington discloses 0.5% Avidity Biosciences (RNA) stake in 13G/A

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Wellington Management Group LLP and affiliates filed an amended Schedule 13G reporting beneficial ownership of Avidity Biosciences common stock. They report beneficial ownership of 723,118 shares, representing about 0.5% of the outstanding common stock as of the event date.

The firms report no sole voting or dispositive power, with 582,610 shares subject to shared voting power and 723,118 shares subject to shared dispositive power. The securities are held in the ordinary course of business for advisory clients, and no single client is reported to hold more than five percent of the class.

Positive

  • None.

Negative

  • None.





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Wellington Management Group LLP
Signature:Taisia Lowe
Name/Title:Regulatory Analyst
Date:02/10/2026
Wellington Group Holdings LLP
Signature:Taisia Lowe
Name/Title:Regulatory Analyst
Date:02/10/2026
Wellington Investment Advisors Holdings LLP
Signature:Taisia Lowe
Name/Title:Regulatory Analyst
Date:02/10/2026

FAQ

What stake does Wellington hold in Avidity Biosciences (RNA)?

Wellington entities report beneficial ownership of 723,118 Avidity Biosciences common shares, representing about 0.5% of the class. These shares are held for investment advisory clients, reflecting a relatively small institutional position disclosed through an amended Schedule 13G filing.

How much voting power does Wellington report in Avidity Biosciences (RNA)?

Wellington reports no sole voting power and shared voting power over 582,610 Avidity Biosciences shares. This means voting decisions on these shares are shared, consistent with their role managing assets for multiple advisory clients rather than holding the position directly.

Who legally owns the Avidity Biosciences (RNA) shares reported by Wellington?

The reported Avidity Biosciences shares are owned of record by clients of the Wellington investment advisers. Wellington Management Group LLP and its related holding companies report beneficial ownership because they control the advisers managing these client accounts, not because they directly own the securities.

Is any Wellington client reported to own over 5% of Avidity Biosciences (RNA)?

No individual client is reported to have the right to receive dividends or sale proceeds for more than five percent of Avidity Biosciences’ common stock. The Schedule 13G specifically states no such client is known to hold that level of economic interest in the class.

Why did Wellington file an amended Schedule 13G for Avidity Biosciences (RNA)?

Wellington filed Amendment No. 2 to update its beneficial ownership information as of December 31, 2025. The filing reflects that its aggregated holding is about 0.5% of Avidity Biosciences’ common stock, bringing the reported stake to five percent or less of the class.
Avidity Biosciences, Inc.

NASDAQ:RNA

RNA Rankings

RNA Latest News

RNA Latest SEC Filings

RNA Stock Data

11.26B
142.57M
4.78%
107.4%
13.66%
Biotechnology
Pharmaceutical Preparations
Link
United States
SAN DIEGO